Financial Performance - In 2024, the total revenue of the company was RMB 1,030,010.44 million, a decrease of 9.73% compared to the previous year[4] - The net profit attributable to the parent company was RMB 126,186.95 million, down 36.08% year-on-year[4] - The net profit attributable to the parent company after deducting non-recurring gains and losses was RMB 101,032.34 million, a decline of 39.32% compared to the previous year[4] Assets and Equity - The company's total assets at the end of 2024 reached RMB 2,803,568.89 million, reflecting a year-on-year growth of 10.65%[6] - The equity attributable to the parent company increased by 5.50% to RMB 1,990,316.54 million[6] Research and Development - The company has increased its R&D investment, which has impacted short-term profitability but aims to drive future growth through innovative products[7] Market Expansion - The company is actively expanding its overseas market presence, resulting in sustained growth in international revenue despite domestic challenges[7] - The decline in domestic revenue is attributed to the slower rollout of domestic equipment update policies and longer market introduction periods for high-end new products[8] Cost Management and Future Outlook - The company is optimizing supply chain management and enhancing employee efficiency to control costs and improve profitability[7] - The company anticipates a potential recovery in overall performance as domestic industry policies are further implemented and the market rebounds[7]
联影医疗(688271) - 2024 Q4 - 年度业绩